IR Insights: Recapping Updates from the 44th Annual J.P. Morgan Healthcare Conference

Forward-Looking Statements

This post and accompanying video contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s projected commercial and financial performance; Moderna’s 2026 financial framework, including projected sales growth and expected operating costs; Moderna’s expected further cost reductions; Moderna’s anticipated commercial growth drivers, including geographic expansion and new product launches; anticipated potential first approvals of flu and flu/COVID combination products in 2026; Moderna’s ability to advance its oncology pipeline; the five-year Phase 2 and Phase 3 melanoma data for intismeran and Phase 2 data for mRNA-4359; the potential of mRNA-4359, including an encouraging clinical signal; Moderna’s cash balance and ability to fund its next phase of innovation; and the potential and timing for future product approvals, data readouts and commercial launches. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this post are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this post.